

Louisiana Medicaid
Diagnosis Code Requirement for AbobotulinumtoxinA (Dysport®)†, IncobotulinumtoxinA (Xeomin®)†,
OnabotulinumtoxinA (Botox®)† and RimabotulinumtoxinB (Myobloc®)†
With Quantity Limits for IncobotulinumtoxinA (-Xeomin®) and OnabotulinumtoxinA (Botox®)

Table 1. Acceptable Diagnosis Codes for Botulinum Toxins

Diagnosis Description	Diagnosis Code	Dysport®	Xeomin®	Botox®	Myobloc®
Axillary Hyperhidrosis	L74.510			✓	
Blepharospasm	G24.5		✓	✓	
Cervical Dystonia	G24.3	✓	✓	✓	✓
Chronic Migraine (Prophylaxis)	G43.7*			✓	
Chronic Sialorrhea	K11.7		✓		✓
Overactive Bladder	N32.81			✓	
Strabismus	H49*, H50*, H51*			✓	
Urinary Incontinence (Detrusor Overactivity Associated with Neurological Disease)	N31.9, N36.44			✓	
<u>Recipients 2 Years of Age or Older (unless otherwise specified) With Upper and/or Lower Limb Spasticity Associated With:</u>		<u>Upper & Lower Limb Up/Low-Adults; Low-Peds>2</u>	<u>Upper Limb</u>	<u>Upper & Lower Limb</u>	
Multiple Sclerosis	G35	✓	✓	✓	
Cerebral Palsy	G80.0, G80.1, G80.2, G80.4, G80.8, G80.9	✓	<u>Adults > 18 years of age</u> ✓	✓	
Spastic Hemiplegia	G81.1*	✓	✓	✓	
Complete Quadriplegia	G82.53	✓	✓	✓	
Incomplete Quadriplegia	G82.54	✓	✓	✓	
Diplegia Of Upper Limb	G83.0	✓	✓	✓	
Monoplegia of Upper Limb	G83.2*	✓	✓	✓	
Monoplegia of Lower Limb	G83.1*, G83.3*	✓		✓	
Monoplegia of Upper Limb Due to Late Effects of Cerebrovascular Disease	I69._31, I69._32, I69._33, I69._34, I69._39	✓	✓	✓	
Monoplegia of Lower Limb Due to Late Effects of Cerebrovascular Disease	I69._41, I69._42, I69._43, I69._44, I69._49	✓		✓	
Hemiplegia Due to Late Effects of Cerebrovascular Disease	I69._51, I69._52, I69._53, I69._54, I69._59	✓	✓	<u>✓</u>	
Intracranial Injury of Other and Unspecified Nature (Traumatic Brain Injury)	S06.1*, S06.2*, S06.3*, S06.4*, S06.5*, S06.6*, S06.8*, S06.9*	✓	✓	✓	
Spinal Cord Injury Without Evidence of Spinal Bone Injury	S14.0*, S14.1_5*, S14.1_6*, S14.1_7*	✓	✓	✓	

†These medications have **Black Box Warnings** and/or may be subject to **Risk Evaluation and Mitigation Strategy (REMS)** under FDA safety regulations; refer to individual prescribing information for details.

*Any number or letter or combination of **UP TO FOUR** numbers and letters of an assigned ICD-10-CM diagnosis code

The underscore (_) can be any ONE number (0-9)

Table 2. Quantity Limits for IncobotulinumtoxinA (Xeomin®) and OnabotulinumtoxinA (Botox®)

Medication	Quantity Limit per Rolling 84-Day Period
IncobotulinumtoxinA (Xeomin®)	400 units
OnabotulinumtoxinA (Botox®)	600 units [Six (6) 100-unit vials OR Three (3) 200-unit vials]

References

Botox (onabotulinumtoxinA) [package insert]. Madison, NJ: Allergan USA, Inc; ~~October 2019~~ July 2020. <https://media.allergan.com/actavis/actavis/media/allergan-pdf-documents/product-prescribing/20190620-BOTOX-100-and-200-Units-v3-0USPI1145-v2-0MG1145.pdf>

Dysport (abobotulinumtoxinA) [package insert]. Basking Ridge, NJ: Ipsen Biopharmaceuticals, Inc; ~~September 2019~~ July 2020. https://www.ipson.com/websites/Ipsen_Online/wp-content/uploads/2020/07/10002305/DYS-US-004998_Dysport-PI-July-2020.pdf

Myobloc (rimabotulinumtoxinB) [package insert]. South San Francisco, CA: Solstice Neurosciences, Inc; August 2019. https://myobloc.com/files/MYOBLOC_PI.pdf

Xeomin (incobotulinumtoxinA) [package insert]. Raleigh, NC: Merz Pharmaceuticals, LLC; August 2020. <https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=ccdc3aae-6e2d-4cd0-a51c-8375bfee9458&type=display>

Revision	Date
Modified to reflect new indications for Dysport® and Xeomin®, included Hemiplegia due to late effects of cerebrovascular disease for Botox®, formatting changes, updated references	September 2020